On the public citation graph
Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer
0 signed · 74 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/path.2022openalex-snapshot
Dual‐colour chromogenic in situ hybridization for testing of HER‐2 oncogene amplification in archival breast tumours
inferredcites →https://doi.org/10.1002/path.2574openalex-snapshot
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis
inferredcites →https://doi.org/10.1007/s00428-007-0424-5openalex-snapshot
Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists
inferredcites →https://doi.org/10.1016/j.humpath.2007.05.004openalex-snapshot
Metallographic in situ hybridization
inferredcites →https://doi.org/10.1016/s0140-6736(07)60028-2openalex-snapshot
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1097/pas.0b013e3181d96231openalex-snapshot
Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma
inferredcites →https://doi.org/10.1097/pas.0b013e3181e70e15openalex-snapshot
Determination of the Her-2/neu Gene Amplification Status in Cytologic Breast Cancer Specimens Using Automated Silver-enhanced In-situ Hybridization (SISH)
inferredcites →https://doi.org/10.1097/pdm.0b013e31816f6374openalex-snapshot
Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays
inferredcites →https://doi.org/10.1097/pdm.0b013e31817f5227openalex-snapshot
The Correlation Between Dual-color Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization in Assessing HER2 Gene Amplification in Breast Cancer
inferredcites →https://doi.org/10.1126/science.3798106openalex-snapshot
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
inferredcites →https://doi.org/10.1136/jcp.2009.062760openalex-snapshot
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma
inferredcites →https://doi.org/10.1158/1535-7163.mct-06-0129openalex-snapshot
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
inferredcites →https://doi.org/10.1186/1746-1596-3-41openalex-snapshot
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
inferredcites →https://doi.org/10.1186/bcr1776openalex-snapshot
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
inferredcites →https://doi.org/10.1186/bcr996openalex-snapshot
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry
inferredcites →https://doi.org/10.1200/jco.2006.09.2775openalex-snapshot
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2007.13.4296openalex-snapshot
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
inferredcites →https://doi.org/10.1309/c4pebgb9ln830tvlopenalex-snapshot
Chromogenic In Situ Hybridization for the Detection of HER-2/neuGene Amplification in Breast Cancer With an Emphasis on Tumors With Borderline and Low-Level Amplification
inferredcites →https://doi.org/10.4048/jbc.2009.12.4.235openalex-snapshot
Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization for HER2 Gene Status in Breast Carcinomas
inferredcites →https://doi.org/10.5858/2007-131-18-asoccoopenalex-snapshot
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4851024openalex-extracted
Comprehensive Review on Computational In-Situ Hybridization (Ish) Digital Pathology Using Image Analysis Techniques: Principles and Applications
inferred← citeshttps://doi.org/10.1007/978-1-4939-2886-6_9openalex-snapshot
Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-1-4939-3444-7_4openalex-snapshot
In Situ Hybridization of Breast Cancer Markers
inferred← citeshttps://doi.org/10.1007/978-3-030-42386-5_5openalex-snapshot
Reporting Core Biopsies: Lesions That Are Highly Suspicious of Malignancy (B4) or Definitely Malignant (B5)
inferred← citeshttps://doi.org/10.1007/s00428-016-1903-3openalex-snapshot
Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment
inferred← citeshttps://doi.org/10.1007/s00428-019-02567-zopenalex-snapshot
What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
inferred← citeshttps://doi.org/10.1007/s12282-014-0533-3openalex-snapshot
Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization
inferred← citeshttps://doi.org/10.1007/s44178-025-00149-5openalex-snapshot
CACA Technical guidelines for holistic integrative management of cancer —— genetic testing
inferred← citeshttps://doi.org/10.1016/j.addr.2016.04.005openalex-snapshot
Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches
inferred← citeshttps://doi.org/10.1016/j.annpat.2011.10.013openalex-snapshot
Détermination de l’amplification de l’oncogène HER-2 dans le cancer du sein invasif par hybridation chromogénique in situ double couleur (dc-CISH) : étude comparative avec l’hybridation fluorescente in situ (FISH)
inferred← citeshttps://doi.org/10.1016/j.arcmed.2012.03.010openalex-snapshot
Effectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma: A Comparative Study
inferred← citeshttps://doi.org/10.1016/j.artmed.2023.102568openalex-snapshot
Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapy
inferred← citeshttps://doi.org/10.1016/j.bmc.2024.117931openalex-snapshot
Harnessing molecular probes for imaging of human epidermal growth factor receptor (HER) family
inferred← citeshttps://doi.org/10.1016/j.humpath.2011.05.019openalex-snapshot
Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
inferred← citeshttps://doi.org/10.1016/j.humpath.2013.07.005openalex-snapshot
Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization
inferred← citeshttps://doi.org/10.1016/j.prp.2013.01.006openalex-snapshot
Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment
inferred← citeshttps://doi.org/10.1016/j.prp.2014.06.031openalex-snapshot
High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer
inferred← citeshttps://doi.org/10.1016/j.prp.2019.01.037openalex-snapshot
HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer
inferred← citeshttps://doi.org/10.1021/acs.chemrev.1c00241openalex-snapshot
Nucleic Acid Tests for Clinical Translation
inferred← citeshttps://doi.org/10.1021/pr501259eopenalex-snapshot
High-Performance Low-Cost Antibody Microarrays Using Enzyme-Mediated Silver Amplification
inferred← citeshttps://doi.org/10.1038/s41467-022-33267-zopenalex-snapshot
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
inferred← citeshttps://doi.org/10.1038/s41523-023-00517-2openalex-snapshot
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion
inferred← citeshttps://doi.org/10.1080/14737159.2018.1440210openalex-snapshot
Bright-fieldin situhybridization detects gene alterations and viral infections useful for personalized management of cancer patients
inferred← citeshttps://doi.org/10.1093/ajcp/aqac179openalex-snapshot
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
inferred← citeshttps://doi.org/10.1093/ajcp/aqw017openalex-snapshot
Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma
inferred← citeshttps://doi.org/10.1093/ajcp/aqw211openalex-snapshot
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
inferred← citeshttps://doi.org/10.1097/01.xej.0000520909.07039.02openalex-snapshot
Fluorescence in-situ hybridization versus chromogenic in-situ hybridization in evaluating HER2 status in breast cancer by adopting tissue microarray technique
inferred← citeshttps://doi.org/10.1097/jto.0b013e31824fe95aopenalex-snapshot
Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1097/pat.0b013e328359cf9aopenalex-snapshot
HER2 testing in breast cancer: an overview of current techniques and recent developments
inferred← citeshttps://doi.org/10.1111/apm.13076openalex-snapshot
Evaluation of analytical accuracy of HER2 status in patients with breast cancer
inferred← citeshttps://doi.org/10.1111/cup.12278openalex-snapshot
Fully automated dual‐color dual‐hapten silver in situ hybridization staining for MYC amplification: a diagnostic tool for discriminating secondary angiosarcoma
inferred← citeshttps://doi.org/10.1111/his.12247openalex-snapshot
Instant‐quality fluorescence in‐situ hybridization as a new tool for HER 2 testing in breast cancer: a comparative study
inferred← citeshttps://doi.org/10.1111/his.13208openalex-snapshot
Counting invasive breast cancer cells in the HER2 silver in‐situ hybridization test: how many cells are enough?
inferred← citeshttps://doi.org/10.1136/jclinpath-2013-201647openalex-snapshot
False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma
inferred← citeshttps://doi.org/10.1136/jcp-2025-210175openalex-snapshot
Chinese guidelines for HER2 testing in breast cancer (2024 edition): summary of key recommendations
inferred← citeshttps://doi.org/10.1177/11782234251407914openalex-snapshot
Comparative Analysis of Equivocal (2+) and Positive (3+) HER2 Immunohistochemistry (IHC) and Bright-Field Dual-Color In Situ Hybridization (DISH) in Primary Breast Cancer From 1,307 Node-Positive Patients
inferred← citeshttps://doi.org/10.1186/1472-6890-13-13openalex-snapshot
Comparison of automated and manual FISH for evaluation of HER2 gene status on breast carcinoma core biopsies
inferred← citeshttps://doi.org/10.1186/1756-0500-6-562openalex-snapshot
Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer
inferred← citeshttps://doi.org/10.1245/s10434-013-3456-xopenalex-snapshot
Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets
inferred← citeshttps://doi.org/10.12809/hkmj144458openalex-snapshot
Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong
inferred← citeshttps://doi.org/10.12809/hkmj154458openalex-snapshot
Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong
inferred← citeshttps://doi.org/10.1309/ajcp6cxs8osrhxiropenalex-snapshot
Bright-Field HER2 Dual In Situ Hybridization (DISH) Assay vs Fluorescence In Situ Hybridization (FISH)
inferred← citeshttps://doi.org/10.1309/ajcpkivvw4obpx6iopenalex-snapshot
Dual HER2 Gene Protein Assay
inferred← citeshttps://doi.org/10.1586/14737159.2015.992416openalex-snapshot
HER2 assessment by silverin situhybridization: where are we now?
inferred← citeshttps://doi.org/10.19127/bshealthscience.836510openalex-snapshot
Prognostic Significance of HER-2 Expression in Gastric Cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-4830804/v1openalex-snapshot
Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast Cancer
inferred← citeshttps://doi.org/10.3390/diagnostics14182089openalex-snapshot
Review of In Situ Hybridization (ISH) Stain Images Using Computational Techniques
inferred← citeshttps://doi.org/10.3748/wjg.v19.i38.6438openalex-snapshot
HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays
inferred← citeshttps://doi.org/10.3748/wjg.v22.i19.4619openalex-snapshot
HER2 testing in gastric cancer: An update
inferred← citeshttps://doi.org/10.4103/egjp.egjp_3_21openalex-snapshot
Agarose cell block and ancillary molecular tests enhance diagnostic efficacy of liquid-based cytology samples
inferred← citeshttps://doi.org/10.4132/jptm.2019.11.03openalex-snapshot
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
inferred← citeshttps://doi.org/10.5858/arpa.2015-0249-oaopenalex-snapshot
Automated Bright-Field Dual-Color In Situ Hybridization for MDM2: Interobserver Reproducibility and Correlation With Fluorescence In Situ Hybridization in a Series of Soft Tissue Consults
inferred← citeshttps://doi.org/10.5858/arpa.2019-0510-oaopenalex-snapshot
HER2 Dual In Situ Hybridization: Correlations and Cautions
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.